CVE:AQS Aequus Pharmaceuticals 8/29/2024 Earnings Report C$0.0050 0.00 (-37.50%) As of 04/25/2025 ProfileEarnings History Aequus Pharmaceuticals EPS ResultsActual EPS-C$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAequus Pharmaceuticals Revenue ResultsActual Revenue$0.16 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAequus Pharmaceuticals Announcement DetailsQuarterDate8/29/2024TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile Aequus Pharmaceuticals Earnings HeadlinesAequus Pharmaceuticals: Top 10 Undervalued Healthcare Sector Stocks on TSX-V (AQS)January 22, 2025 | theglobeandmail.comAequus Pharmaceuticals Reports Revenue Growth Amid RestructuringNovember 9, 2024 | markets.businessinsider.comThis Could Be the Most Profitable Season of Your LifeInstitutional money is pouring in. Bitcoin ETFs are live. Altcoin adoption is accelerating. This is the same point in every cycle when crypto enters its most explosive phase — and two experts are showing how to ride it. Inside The Crypto Code Workshop, you’ll get their step-by-step system and $10 in free Bitcoin for attending.July 18 at 2:00 AM | Crypto Swap Profits (Ad)Aequus Pharmaceuticals Inc. (AQSZF)September 5, 2024 | finance.yahoo.comAequus Pharmaceuticals Inc (AQS)August 3, 2024 | investing.comClosing Bell: Aequus Pharmaceuticals Inc down on Friday (AQS)July 23, 2024 | theglobeandmail.comSee More Aequus Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aequus Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aequus Pharmaceuticals and other key companies, straight to your email. Email Address About Aequus PharmaceuticalsAequus Pharmaceuticals (CVE:AQS) operates as a specialty pharmaceutical company in Canada. The company markets ZIMED PF, a preservative-free bimatoprost ophthalmic solution. It also develops a range of prescription-free dry eye products under the OPTASE name; and REV-0100 for the treatment of stargardt disease. The company was incorporated in 2013 and is headquartered in Vancouver, Canada.View Aequus Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025)General Motors (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
